Appareil pulmonaire
CHRYSALIS-2 (73841937NSC1001 )
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-;73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in;Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in;Participants With Advanced Non-Small Cell Lung Cancer
Paris
NICOLAS GIRARD